Additional analytical results of the US-based Phase 2b clinical trial of regenerative cell medicine SB623 for the treatment of chronic motor deficit from ischemic stroke, and review of plans to initiate clinical trials for the ischemic stroke and hemorrhagic stroke programs in Japan based on these results
Akihiro Tsujimura appointed Executive Vice President and COO
Christopher Horan Joins SanBio as Corporate Officer and Chief Technical Operations Officer
Financial Results Briefing for Fiscal Year Ended January 31, 2020: Q&A Summary
Joint Research to Investigate the Efficacy of SB623 in the Treatment of Traumatic Brain Injury at Subacute Phase
Joint Research with View to Developing Regenerative Medicine Product for Type 1 Diabetes by Producing Pancreatic Beta Cells Through Direct Reprogramming of Bone Marrow-Derived Mesenchymal Stem Cells
Q&A Regarding Announcements on December 13, 2019 Concerning “Consolidated Financial Results for the Nine Months Ended October 31, 2019” and “Decision to Terminate a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America,”
SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
Agreement on Joint Research into SB623 for Indication of Retinal Disease
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury
